Integra Lifesciences Gets a Buy Rating from Jefferies

By Ryan Adsit

Jefferies analyst Raj Denhoy reiterated a Buy rating on Integra Lifesciences (NASDAQ: IART) on October 10 and set a price target of $58. The company’s shares closed yesterday at $49.59.

According to, Denhoy is a 5-star analyst with an average return of 12.8% and a 63.7% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Varian Medical Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Integra Lifesciences is Strong Buy and the average price target is $56.40, representing a 13.7% upside.

In a report issued on September 26, Oppenheimer also assigned a Buy rating to the stock.

Integra Lifesciences’ market cap is currently $3.84B and has a P/E ratio of 60.48. The company has a book value ratio of 4.2930.

Based on the recent corporate insider activity of 68 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IART in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Specialty Surgical Solutions, and Orthopedics & Tissue Technologies segments.